Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel mycoplasma hyopneumoniae strain and its vaccine composition

A technology of Mycoplasma hyopneumoniae and vaccine composition, applied in vaccines, multivalent vaccines, bacteria and other directions, can solve problems such as poor clinical prevention and treatment effects, and achieve the effect of not affecting weight gain and small loss of lung lesions

Active Publication Date: 2017-09-22
PULIKE BIOLOGICAL ENG INC +1
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The above literature shows that the clinical prevention and treatment effect of Mycoplasma hyopneumoniae J strain used in the vaccine is not good for the clinical prevention and treatment of Mycoplasma hyopneumoniae

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel mycoplasma hyopneumoniae strain and its vaccine composition
  • Novel mycoplasma hyopneumoniae strain and its vaccine composition
  • Novel mycoplasma hyopneumoniae strain and its vaccine composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Embodiment 1, isolation and identification of Mycoplasma hyopneumoniae HN0613 strain

[0042] 1. Materials and methods

[0043] 1.1 Materials

[0044] 1.1.1 Source of disease materials In 2006, 16 lungs suspected of being caused by mycoplasma swine pneumonia were collected from various places in Henan Province.

[0045] 1.1.2 Medium Mycoplasma hyopneumoniae Friis medium was purchased from BD Company; pig serum was purchased from GIBCO Company; phenol red indicator was purchased from American AMRESCO Company.

[0046] 1.1.3 Biochemical reagents Chemical reagents were purchased from Sinopharm Chemical Reagent Co., Ltd. Bacterial Genomic DNA Extraction Kit was purchased from TIANGEN Company, and Dieter's Staining Kit was purchased from Chongqing Pangtong Medical Instrument Co., Ltd. Biochemical identification reagents were purchased from Hangzhou Tianhe Microbiological Reagent Co., Ltd.

[0047] 1.1.4 Negative and positive serum Rabbit anti-Mycoplasma hyopneumoniae lip...

Embodiment 2

[0084] The preparation of the combination vaccine antigen of embodiment 2 mycoplasma pneumonia vaccine composition and porcine circovirus type 2, mycoplasma hyopneumoniae

[0085] 1.1 Preparation of bacteria (poison) species for production

[0086] The preparation of porcine circovirus type 2 SH: the virus seed PCV2SH strain was diluted 1:9 with MEM liquid medium (prepared according to the instruction manual with the MEM dry powder medium purchased from Invitrogen Company of the United States), and then diluted by 5% of the volume of the cell culture medium. % inoculated on PK15 (ATCC, preservation number is CCL-33) monolayer cells, adsorbed at 37°C for 30 minutes, added cell maintenance solution (add 4% calf serum and 2mmol / L D-glucosamine hydrochloride in MEM liquid medium) ), cultured at 37°C for 4 days, frozen and thawed 2 to 3 times, and the virus was harvested, and the virus titer was 10 6.5 TCID 50 / ml.

[0087] Preparation of Mycoplasma hyopneumoniae strains: After ...

Embodiment 3

[0124] Embodiment 3, the preparation of composition vaccine:

[0125] In order to compare the immune effect of the vaccine, Montanide is selected when preparing the composition vaccine TM Gel adjuvant (produced by SEPPIC, France) was used to prepare porcine circovirus disease (whole virus antigen or ORF2 protein), dual inactivated vaccine against mycoplasma pneumoniae and single vaccine against mycoplasma pneumoniae. The specific configuration is as follows:

[0126] Preparation method: formula is as table 5. Get the PCV2 antigen and Mycoplasma hyopneumoniae antigen prepared in Example 1. The concentrated antigen solution was prepared into a mixed antigen solution or directly prepared into an antigen solution according to the final antigen content in the joint vaccine and the single vaccine, and then the antigen solution was mixed with Gel01 adjuvant (produced by SEPPIC, France) at a ratio of 90:10 (V / V) mixing, replenish volume with PBS solution with pH 7.2 and stir at 30...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a Mycoplasma hyopneumoniae strain HN0613 strain which is isolated and identified as having better immunogenicity, and also provides the Mycoplasma hyopneumoniae antigen prepared by the above-mentioned Mycoplasma hyopneumoniae HN0613 strain and the Mycoplasma hyopneumoniae pneumonia vaccine containing the Mycoplasma hyopneumoniae antigen . The present invention also provides a dual combination vaccine of porcine circovirus type 2 and mycoplasma hyopneumoniae, comprising PCV2 antigen (inactivated porcine circovirus type 2 antigen or PCV2 ORF2 protein), inactivated mycoplasma hyopneumoniae and vaccine adjuvant agent. The combination vaccine of the present invention can prevent porcine circovirus disease and swine mycoplasma pneumonia with one shot of the vaccine, and has a preventive and protective effect on mycoplasma hyopneumoniae infection.

Description

[0001] This case is a divisional application of invention patent application 201210224389.9, and the filing date of the original application is June 29, 2012. technical field [0002] The invention relates to a novel mycoplasma hyopneumoniae and a vaccine composition, belonging to the field of veterinary vaccines. Background technique [0003] Mycoplasma hyopneumoniae is the causative agent of mycoplasma pneumonia in swine. Mycoplasma swine pneumonia is a chronic consumptive respiratory disease of pigs with a high clinical infection rate. The disease causes a persistent cough that lasts for several weeks, loss of luster in the coat, growth retardation, and a stocky appearance. Once the pig herd is infected with Mycoplasma hyopneumoniae, it is difficult to remove it, which not only seriously affects the growth and development of the pig herd, but also increases the dosage of drugs, and is prone to secondary infection of PRRSV (porcine blue ear disease virus), PCV (porcine ci...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N1/20A61K39/02A61P31/04C12R1/35
CPCA61K39/0241A61K39/12A61K2039/54A61K2039/545A61K2039/70C12N2750/10034C12N1/205C12R2001/35
Inventor 田克恭张许科孙进忠白朝勇
Owner PULIKE BIOLOGICAL ENG INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com